Culture

 

British Queen celebrates

image image image image
London’s oldest public park reopens after major makeover Read the Full Story
Ukraine strikes deep into Russia, destroys dozens of strategic bombers in major drone attack Read the Full Story
UK defence review to send ‘message to Moscow,’ says Healey Read the Full Story
Government completes exit from NatWest after nearly 17 years Read the Full Story
* * * *

UK News

World News

Media

 

Following approval from the British health regulator for Eli Lilly's new weight-loss treatment, Health Secretary Steve Barclay expressed optimism about the potential benefits for thousands of

obese individuals in the UK. The drug, Zepbound (also known as Mounjaro or tirzepatide), received the green light from both U.S. and UK regulators, offering a formidable competitor to Novo Nordisk's Wegovy in addressing rising obesity rates.

In a statement, Barclay highlighted the drug's potential to assist people struggling with obesity and alleviate weight-related health issues when combined with proper diet and physical activity. He emphasized the impact on reducing waiting lists and potential cost savings for the National Health Service (NHS).

However, Barclay noted that additional approvals were necessary before the drug could be included in NHS coverage.